Logotype for Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries (TEVA) R&D Day 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Teva Pharmaceutical Industries Limited

R&D Day 2026 summary

15 Nov, 2026

Pipeline overview and program updates

  • Pipeline includes 10 innovative assets, with seven late-stage programs representing more than $10B in combined peak-sales potential; four homegrown immunology programs include duvakitug, anti-IL-15, PD-1/IL-2 and TSLP/IL-13.

  • Duvakitug is advancing in ulcerative colitis, Crohn’s disease, hidradenitis suppurativa and fibrostenotic Crohn’s disease; anti-IL-15 spans celiac disease, vitiligo and alopecia areata.

  • Early antibody programs include TL1A/IL-23 and TSLP/IL-13, with additional engineered candidates in discovery.

  • Emrusolmin’s Phase 2 study is being discontinued after meeting its futility milestone; anti-TL1A/IL-23 was added to the preclinical pipeline.

Clinical trial data and development milestones

  • Anti-IL-15 Phase 2a celiac study met its Week 8 primary endpoint: less villus damage than placebo (p<0.05; n=43) and reduced inflammatory IEL markers; Phase 2b is planned for H2 2027.

  • In vitiligo, ~75% of patients reported facial improvement after two subcutaneous doses 12 weeks apart; 19 patients completed the proof-of-concept analysis. TEV-'408 is advancing to Phase 2/3.

  • Duvakitug Phase 2b showed placebo-adjusted clinical remission of 27.4% in ulcerative colitis at Week 14; cross-trial maintenance comparisons suggest potential, but are not head-to-head.

  • Anti-PD-1/IL-2 Phase 1 interim data in 25 participants showed one complete and six partial responses across 11 tumor types, with no safety signals reported by Oct. 29, 2026.

  • DARI Phase 3 enrollment exceeded 2,700, with >90% of required exacerbation events; ecopipam is filed with FDA, and approval is targeted for H1 2027.

R&D strategy and innovation priorities

  • R&D model prioritizes clinically validated biology, differentiated high-potential assets, unmet need, accelerated development and data-driven capital allocation.

  • Antibody engineering combines disease-biology insights with precision formats, including pH-tuned TL1A/IL-23 blockade and dual-specific TSLP/IL-13 design.

  • Accelerated development includes direct Phase 1-to-3 and seamless Phase 2/3 designs, with estimated time savings of 4 to >24 months across cited examples.

  • Launch cadence targets one innovative product annually through 2030, with up to nine marketed innovative assets by 2030, subject to approval.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Teva Pharmaceutical Industries